Last reviewed · How we verify
Lactobacillus fermentum LC40
Lactobacillus fermentum LC40 is a Biologic drug developed by Universidad Complutense de Madrid. It is currently in Phase 2 development.
At a glance
| Generic name | Lactobacillus fermentum LC40 |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus fermentum LC40 CI brief — competitive landscape report
- Lactobacillus fermentum LC40 updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI
Frequently asked questions about Lactobacillus fermentum LC40
What is Lactobacillus fermentum LC40?
Lactobacillus fermentum LC40 is a Biologic drug developed by Universidad Complutense de Madrid.
Who makes Lactobacillus fermentum LC40?
Lactobacillus fermentum LC40 is developed by Universidad Complutense de Madrid (see full Universidad Complutense de Madrid pipeline at /company/universidad-complutense-de-madrid).
What development phase is Lactobacillus fermentum LC40 in?
Lactobacillus fermentum LC40 is in Phase 2.